Premium
Galectin‐1 and galectin‐3 expression in human bladder transitional‐cell carcinomas
Author(s) -
Cindolo Luca,
Benvenuto Giovanna,
Salvatore Paola,
Pero Raffaela,
Salvatore Gaetano,
Mirone Vincenzo,
Prezioso Domenico,
Altieri Vincenzo,
Bruni Carmelo Bruno,
Chiariotti Lorenzo
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990219)84:1<39::aid-ijc8>3.0.co;2-e
Subject(s) - urothelium , galectin , galectin 3 , transitional cell carcinoma , galectin 1 , bladder cancer , western blot , pathology , biology , stage (stratigraphy) , cell , cancer research , carcinoma in situ , cancer , carcinoma , urinary bladder , medicine , immunology , gene , paleontology , biochemistry , genetics
Galectin‐1 and galectin‐3 are galactoside‐binding proteins involved in different steps of tumor progression and potential targets for therapy. We have investigated the expression of these galectins in 38 human bladder transitional‐cell carcinomas of different histological grade and clinical stage and in 5 normal urothelium samples. Galectin‐1 mRNA levels were highly increased in most high‐grade tumors compared with normal bladder or low‐grade tumors. Western blot and immuno‐histochemical analysis of normal and neoplastic tissues revealed a higher content of galectin‐1 in tumors. Galectin‐3 mRNA levels were also increased in most tumors compared with normal urothelium, but levels were comparable among tumors of different histological grade. Int. J. Cancer (Pred. Oncol.) 84:39–43, 1999. © 1999 Wiley‐Liss, Inc.